Faculty Assistant

Laisa Eimont
Schultz Laboratory, 419
Phone: 609-258-2933
Fax: 609-258-1701

Research Focus

The Myhrvold lab develops CRISPR-based technologies for studying viral and host RNA, with an emphasis on technologies that will allow us to better understand biological processes such as transcriptional regulation and RNA localization. We also apply these technologies to detect and destroy viral RNAs, with a focus on SARS-CoV-2, the causative agent of COVID-19.

Quantitative, highly multiplexed nucleic acid detection with Cas13

We are developing highly multiplexed Cas13-based technologies for quantitative nucleic acid detection. This builds on our massively multiplexed nucleic acid detection technology CARMEN. Initially, we will develop quantitative versions of CARMEN that will allow us to measure gene expression (rather than simply indicating the presence or absence of nucleic acids). We will also develop versions of CARMEN that are easier to deploy widely, allowing people to use CARMEN in resource-limited settings where there are many circulating viral infections.

Applying Cas13 to systematically study host-pathogen interactions

We will perform high-throughput experiments to understand the rules governing Cas13 targeting of viral RNA. We will also apply Cas13 to experimentally study host-pathogen interactions, using viruses such as influenza and SARS-CoV-2 as model systems. Our goal is to take a systems biology approach by simultaneously measuring the dynamics of a core set of viral and host genes involved in infection using CARMEN, while simultaneously altering infection conditions (such as multiplicity of infection, cells type, and viral or host genotype). We will follow up on these experiments with infections in animal models, harvesting cells from many different infected tissues.

Cas13-based technologies to perturb and readout RNA dynamics

CRISPR-Cas9 has revolutionized our ability to study and manipulate genomic information. Developing Cas13-based technologies can revolutionize the way we study and manipulate RNA. We are developing a variety of Cas13-based technologies to perturb and readout RNA in high throughput. We work closely with colleagues in the department to apply our new technologies to study diverse biological problems. Our work will advance the field of RNA biotechnology, allowing us to unlock the secrets of gene expression, regulation, and function.

Research Areas
Chemical Biology
  • STAT Magazine Wunderkind Award (2020)
  • Forbes 30 Under 30, Healthcare category (2019)
  • John and Fannie Hertz Foundation Graduate Fellow (2011-2016)
Selected Recent Publications

Hayden C. Metsky†, Nicole L. Welch, Nicholas J. Haradhvala, Laurie Rumker, Yibin B. Zhang, Priya P. Pillai, David K. Yang, Cheri M. Ackerman, Juliane Weller, Paul C. Blainey, Cameron Myhrvold*, Michael Mitzenmacher*, and Pardis C. Sabeti*. 11/28/2020. “Efficient design of maximally active and specific nucleic acid diagnostics for thousands of viruses.

Jon Arizti-Sanz*, Catherine A Freije*, Alexandra C Stanton, Chloe K Boehm, Brittany A Petros, Sameed Siddiqui, Bennett M Shaw, Gordon Adams, Tinna-Solveig F Kosoko-Thoroddsen, Molly E Kemball, Jessica N Uwanibe, Jacob E Lemieux, Fehintola V Ajobasile, Philomena E Eromon, Robin Gross, Loni Wronka, Katie Caviness, Lisa E Hensley, Nicholas H Bergman, Bronwyn L MacInnis, Christian T Happi, Pardis C Sabeti*, and Cameron Myhrvold*†. 11/20/2020. “Integrated sample inactivation, amplification, and Cas13-based detection of SARS-CoV-2.” Nature Communications, 11.

Cheri M Ackerman*, Cameron Myhrvold*†, Sri Gowtham Thakku, Catherine A Freije, Hayden C Metsky, David K Yang, Simon H Ye, Chloe K Boehm, Tinna-Sólveig F Kosoko-Thoroddsen, Jared Kehe, Tien G Nguyen, Amber Carter, Anthony Kulesa, John R Barnes, Vivien G Dugan, Deborah T Hung, Paul C Blainey*†, and Pardis C Sabeti*. 4/29/2020. “Massively multiplexed nucleic acid detection with Cas13.” Nature, 582, 7811, Pp. 277-282.

Hayden C Metsky*, Catherine A Freije*, Tinna-Solveig F Kosoko-Thoroddsen, Pardis C Sabeti, and Cameron Myhrvold*†. 3/2/2020. “CRISPR-based surveillance for COVID-19 using genomically-comprehensive machine learning design.

Catherine A Freije*†, Cameron Myhrvold*†, Chloe K Boehm, Aaron E Lin, Nicole L Welch, Amber Carter, Hayden C Metsky, Cynthia Y Luo, Omar O Abudayyeh, Jonathan S Gootenberg, Nathan L Yozwiak, Feng Zhang, and Pardis C Sabeti†. 2019. “Programmable Inhibition and Detection of RNA Viruses Using Cas13.” Mol Cell, 76, 5, Pp. 826-837.e11.

Cameron Myhrvold*†, Catherine A Freije*†, Jonathan S Gootenberg, Omar O Abudayyeh, Hayden C Metsky, Ann F Durbin, Max J Kellner, Amanda L Tan, Lauren M Paul, Leda A Parham, Kimberly F Garcia, Kayla G Barnes, Bridget Chak, Adriano Mondini, Mauricio L Nogueira, Sharon Isern, Scott F Michael, Ivette Lorenzana, Nathan L Yozwiak, Bronwyn L MacInnis, Irene Bosch, Lee Gehrke, Feng Zhang, and Pardis C Sabeti†. 2018. “Field-deployable viral diagnostics using CRISPR-Cas13.” Science, 360, 6387, Pp. 444-448.

Jonathan S Gootenberg*, Omar O Abudayyeh*, Jeong Wook Lee, Patrick Essletzbichler, Aaron J Dy, Julia Joung, Vanessa Verdine, Nina Donghia, Nichole M Daringer, Catherine A Freije, Cameron Myhrvold, Roby P Bhattacharyya, Jonathan Livny, Aviv Regev, Eugene V Koonin, Deborah T Hung, Pardis C Sabeti, James J Collins†, and Feng Zhang†. 2017. “Nucleic acid detection with CRISPR-Cas13a/C2c2.” Science, 356, 6336, Pp. 438-442.